Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 6 (9), ofz228
eCollection

Vitamin D and Acute Respiratory Infections-The PODA Trial

Affiliations

Vitamin D and Acute Respiratory Infections-The PODA Trial

John F Aloia et al. Open Forum Infect Dis.

Abstract

Background: There is considerable heterogeneity in clinical trials examining the role of vitamin D in the prevention of acute respiratory infections (ARIs).

Methods: The primary aim of the Physical Performance, Osteoporosis, and Vitamin D in Older African-American Women (PODA) trial was the prevention of bone loss and decline in physical performance. A questionnaire about ARIs was administered every 3 months for 3 years to 260 black American women in a double-blind randomized clinical trial that had a placebo group and a vitamin D supplementation group. The serum 25(OH)D level was maintained >30 ng/mL in the vitamin D group.

Results: Serum 25(OH)D was maintained >30 ng/mL in 90% of the active group, whereas levels approximated those associated with the recommended dietary allowance (20 ng/mL) in the placebo group. There was no difference in occurrence of ARIs in the treatment group vs the placebo group. ARIs were not related to total or free 25(OH)D, which were measured at baseline and annually for 36 months.

Conclusions: Vitamin D supplementation sufficient to maintain serum 25(OH)D >30 ng/mL does not prevent ARIs in older African American women.

Clinicaltrialsgov registration number: NCT01153568.

Keywords: acute respiratory infection; osteoporosis; vitamin D; vitamin D metabolites.

Figures

Figure 1.
Figure 1.
Flow diagram for the study. Two hundred fifteen of the 365 exclusions were due to having a high 25(OH)D level. In both the placebo group and vitamin D group, none of the dropouts were due to a gastrointestinal complaint. One dropout in the vitamin D group represents a subject found to have primary hyperparathyroidism at the 3-month visit. Dropouts designated as “other” were due to relocation out of the state or country, general health issues, and 1 subject who was withdrawn by the principal investigator after having gastric bypass surgery, as this would affect vitamin D absorption.
Figure 2.
Figure 2.
Predicted probability of acute respiratory infections over time estimated by the mixed-effects logistic regression model.

Similar articles

See all similar articles

References

    1. Cannell JJ, Vieth R, Umhau JC, et al. Epidemic influenza and vitamin D. Epidemiol Infect 2006; 134:1129–40. - PMC - PubMed
    1. Aloia JF, Li-Ng M. Re: epidemic influenza and vitamin D. Epidemiol Infect 2007; 135:1095–6; author reply 1097–8. - PMC - PubMed
    1. Li-Ng M, Aloia JF, Pollack S, et al. A randomized controlled trial of vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections. Epidemiol Infect 2009; 1–9. - PubMed
    1. Urashima M, Segawa T, Okazaki M, et al. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am J Clin Nutr 2010; 91:1255–60. - PubMed
    1. Laaksi I, Ruohola JP, Mattila V, et al. Vitamin D supplementation for the prevention of acute respiratory tract infection: a randomized, double-blinded trial among young Finnish men. J Infect Dis 2010; 202:809–14. - PubMed

Associated data

Feedback